EP4

Notes

original target text: EP4 antagonist

EP4 is a cell-surface receptor for prostaglandin E2 (PGE2), a lipid signaling molecule produced at sites of tissue injury, inflammation, and within tumors. EP4 belongs to a family of four PGE2 receptors (EP1–EP4), each coupling to distinct intracellular signaling machinery and producing different, sometimes opposing, physiological effects. EP4 activation generally dampens immune responses and promotes several pro-tumor processes, including suppression of cytotoxic immune cells, support of blood vessel formation feeding tumors, and remodeling of the surrounding tissue. Because tumors often generate abundant PGE2 to create an immunosuppressive microenvironment, blocking EP4 with an antagonist is a strategy intended to restrain that suppression and allow immune cells to act against malignant tissue more effectively. EP4 signaling also participates in normal physiology such as maintenance of the gastrointestinal lining, kidney blood flow, and bone remodeling, meaning its modulation carries effects beyond the disease of interest. The rationale for targeting this specific receptor, rather than blocking prostaglandin synthesis broadly, is to selectively interrupt the immunosuppressive arm of PGE2 signaling while leaving other prostaglandin-dependent processes, such as protective effects in the gut, comparatively undisturbed. This mechanism is primarily of interest in oncology, often considered alongside immune-modulating therapies, though prostaglandin signaling is relevant to inflammatory and fibrotic conditions as well.